lutetium-177 DOTATATE
Selected indexed studies
- Lutetium Lu 177 Dotatate. (, 2006) [PMID:30000023]
- Lutetium-177 DOTATATE: A Practical Review. (Pract Radiat Oncol, 2022) [PMID:35717045]
- Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. (N Engl J Med, 2017) [PMID:28076709]
_Worker-drafted node — pending editorial review._
Connections
lutetium-177 DOTATATE is a side effect of
Sources
- Alpha and Beta Radiation for Theragnostics. (2024) pubmed
- Lutetium Lu 177 Dotatate. (2006) pubmed
- Lutetium-177 DOTATATE: A Practical Review. (2022) pubmed
- Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. (2017) pubmed
- ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. (2022) pubmed
- ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. (2022) pubmed
- Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome. (2022) pubmed
- Gastroenteropancreatic Neuroendocrine Tumors. (2018) pubmed
- Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. (2018) pubmed
- Lutetium 177 dotatate induced acute myeloid leukemia. (2020) pubmed